Trevi Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Trevi Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $66.00K, a 11.86% increase year-over-year.
- Trevi Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $59.00K, a 63.89% increase year-over-year.
- Trevi Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- Trevi Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $59.00K, a 73.53% increase year-over-year.
- Trevi Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $118.00K, a 68.57% increase from fiscal 2024.
- Trevi Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $70.00K, a 2.94% increase from fiscal 2023.
- Trevi Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $68.00K, a 21.43% increase from fiscal 2022.
- Trevi Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $56.00K, a 43.59% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $66.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $118.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2025-06-30 | $59.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $70.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2024-06-30 | $34.00K 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $68.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | |
| 2023-06-30 | $33.00K 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $56.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $23.00K 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $39.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2021-06-30 | $17.00K 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $12.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2020-06-30 | $3.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |